Literature DB >> 32572916

Proliferation and migration of hepatocellular carcinoma are accelerated by LINC01287 via the miR-559/TCF12 axis.

Y-B Song1, Z Yu, A-Q Fu, D-M Zhou.   

Abstract

OBJECTIVE: To uncover the role of LINC01287 in the progression of hepatocellular carcinoma (HCC) and the indicated molecular mechanism. PATIENTS AND METHODS: Relative levels of LINC01287 and miR-559 in 32 pairs of HCC tissues and normal ones, as well as HCC cell lines were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Receiver operating characteristic (ROC) curves and Kaplan-Meier curves were depicted for assessing the diagnostic and prognostic potentials of LINC01287 in HCC, respectively. Proliferative and migratory capacities in HCC cells influenced by LINC01287 were assessed by cell counting kit-8 (CCK-8) and transwell assay, respectively. The regulatory loop LINC01287/miR-559/TCF12 was ascertained by Dual-Luciferase reporter assay. The involvement of the regulatory loop in the progression of HCC was examined via rescue experiments.
RESULTS: LINC01287 was upregulated in HCC tissues and cell lines, whereas miR-559 was downregulated. LINC01287 displayed certain diagnostic and prognostic potentials in HCC. Knockdown of LINC01287 could inhibit proliferative and migratory capacities in HCC cells. The regulatory loop LINC01287/miR-559/TCF12 was responsible for the aggravation of HCC.
CONCLUSIONS: LINC01287 drives proliferative and migratory capacities in HCC via targeting the miR-559/TCF12 axis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32572916     DOI: 10.26355/eurrev_202006_21496

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  1 in total

1.  Long intergenic noncoding RNA LINC01287 drives the progression of cervical cancer via regulating miR-513a-5p/SERP1.

Authors:  Yixiang Hu; Wenyou Zhang; Zheng Liu; Qichang Xing; Renzhu Liu; Qingzi Yan; Wencan Li; Xiang Liu
Journal:  Hum Cell       Date:  2022-07-27       Impact factor: 4.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.